ClinicalTrials.gg
CompletedNCT00810199Updated Jul 18, 2014Results posted

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] and methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 137 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-18.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
556
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 113 studies testing methotrexate in Arthritis, Rheumatoid — 8 open to participants now, 10 under way, 2 of them phase 3. Methotrexate · Arthritis, Rheumatoid.

Enrollment
13th of 113
556 · median 130
Started
2009
with 8 others
Phase 3
47 of 113
1 open now
Registered
35th of 113
by date
Lead sponsor
28 of 113
Hoffmann-La Roche

Among the 113 studies testing methotrexate in Arthritis, Rheumatoid, this one is the 13th largest by enrollment, is one of 9 that started in 2009, is one of 47 in phase 3, and was the 35th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

8 of the 113 studies testing methotrexate in Arthritis, Rheumatoid are open now, in 5 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About methotrexate

Methotrexate: first FDA approval 1953 (METHOTREXATE SODIUM), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 113 studies testing methotrexate in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis. Patients receiving methotrexate treatment will be randomized to receive either a) tocilizumab 8 mg intravenous (iv) every 4 weeks + methotrexate orally (po) weekly or b) tocilizumab 8 mg iv every 4 weeks + placebo po weekly. After the first 24 weeks of blinded treatment, treatment adjustments (increase or decrease of treatment intensity) may be introduced at intervals, based on response. The anticipated time on study treatment is up to 3 years, and the target sample size is approximately 470 patients.

03

Conditions studied

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients, ≥ 18 years of age;
  • moderate to severe active rheumatoid arthritis (Disease Activity Score (DAS28) > 4.4);
  • inadequate response to methotrexate;
  • on a stable dose of ≥ 15mg/week methotrexate for at least 6 weeks.

Exclusion criteria

Exclusion Criteria:

  • prior treatment with a biologic;
  • Rheumatoid arthritis (RA) functional class IV;
  • known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections;
  • evidence of active malignant disease.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
556 participants (actual)

Study arms

  • Experimental
    Tocilizumab + Methotrexate

    Tocilizumab 8 mg/kg (up to 800 mg) intravenous (IV) once every 4 weeks + weekly oral methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drugs (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded methotrexate if a flare occurred.

    Drug: tocilizumab [RoActemra/Actemra] · Drug: methotrexate

  • Placebo comparator
    Tocilizumab + Placebo

    Tocilizumab 8 mg/kg (up to 800 mg) IV once every 4 weeks + weekly oral placebo to methotrexate continuing at the patient's pre-study dose for 24 weeks. Patients taking oral corticosteroids remained on their pre-study dose (up to 10 mg/day). Week 24 to Week 52 the dose of tocilizumab and placebo to methotrexate remained the same. Based on DAS28 assessments, corticosteroid dose was adjusted and disease-modifying antirheumatic drug (DMARDS) added. Week 52 to Week 104, based on the DAS28 assessment, treatment was adjusted to one of four protocol specified treatment regimens: Treatment tapering, Continued treatment, Treatment intensification or Maintenance treatment. After Week 100, patients who discontinued tocilizumab because of remission were retreated with the last effective dose of tocilizumab or blinded placebo to methotrexate if a flare occurred.

    Drug: tocilizumab [RoActemra/Actemra] · Drug: placebo

Interventions

  • Drugtocilizumab [RoActemra/Actemra]

    Drug page: Tocilizumab

    tocilizumab 8 mg IV every 4 weeks.

    Also known as: RoActemra/Actemra

  • Approximately 15-17 mg methotrexate capsule orally once a week.

  • Drugplacebo

    Placebo matching methotrexate capsule taken orally once a week.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With American College of Rheumatology (ACR20) Response

    ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Baseline, Weeks 24, 52, 104

  2. Percentage of Participants With ACR50 Response

    ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Baseline, Weeks 24, 52, 104

  3. Percentage of Participants With ACR70 Response

    ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Baseline, Weeks 24, 52, 104

  4. Percentage of Participants With ACR90 Response

    ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: Baseline, Weeks 24, 52, 104

  5. Time to First ACR20 Response

    Time in days from first administration of study drug until ACR20 response. ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: 104 Weeks

  6. Time to First ACR50 Response

    Time in days from first administration of study drug until ACR50 response. ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate).

    Time frame: 104 Weeks

  7. Time to First ACR70 Response

    Time in days from first administration of study drug until ACR70 response. ACR70 response is defined as a ≥ 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: 104 Weeks

  8. Time to First ACR90 Response

    Time in days from first administration of study drug until ACR90 response. ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

    Time frame: 104 Weeks

  9. Area Under Curve (AUC) DAS28

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. AUC DAS28 was averaged over study days. Analysis of Covariance was adjusted for Baseline DAS28 as a covariate and treatment group and region as fixed factors. Higher calculated AUC values are worse (indicate higher disease activity).

    Time frame: Baseline to Week 24

  10. Percentage of Participants With Disease Activity Score 28 (DAS28) Remission

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

    Time frame: Week 52

  11. Percentage of Participants With DAS28 Low Disease Activity (LDAS)

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2.

    Time frame: Weeks 24, 52

  12. Change From Baseline in DAS28 Score

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A higher value indicated higher disease activity. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52

  13. Percentage of Participants With Good or Moderate European League (EULAR) DAS28 Responses

    The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. European League Against Rheumatism (EULAR) Good response: DAS28 ≤ 3.2 or a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \> 3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.

    Time frame: Baseline, 24, 52

  14. Change From Baseline in Swollen Joint Count

    66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52

  15. Change From Baseline in Tender Joint Count

    68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52

  16. Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (VAS)

    The patients global assessment of disease activity was assessed on a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52

  17. Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale (VAS)

    The physician global assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52

  18. Change From Baseline in Patient Global Assessment of Pain (VAS)

    The patient assessed their pain using a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52

  19. Change From Baseline in Erythrocyte Sedimentation Rate (ESR)

    Blood was collected for Erythrocyte Sedimentation Rate (ESR) (a test that assesses tissue inflammation) and was analyzed at a local laboratory. ESR was measured in millimeters/hour (mm/hr). A reduction in the level is considered an improvement.

    Time frame: Baseline, Weeks 24, 52

  20. Change From Baseline in C-Reactive Protein (CRP)

    Blood was collected for C-Reactive Protein (CRP) (a test for analysis of inflammatory and infectious disorders) and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL). A reduction in the level is considered an improvement.

    Time frame: Baseline, Weeks 24, 52

  21. Change From Baseline in the Health Assessment Questionnaire Disability Index

    The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52

  22. Change From Baseline in Total Genant Modified Sharp Scores (GSS)

    Radiographs were taken of each hand and foot at Baseline, Weeks 24, 52 and104 and were evaluated using the Genant modified method according to Sharp. Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Joint Narrowing Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum total erosion score in the hands is 98 and in the feet 42. The maximum scores for joint space narrowing (JSN) in the hands was104 and in the feet 48. The total score was the sum of scores for erosions and JSN. The maximum total modified GSS was 292. A lower number change from Baseline was better. Analysis of covariance model, with Baseline DAS28 as a covariate and treatment and site as fixed factors.

    Time frame: Baseline, Weeks 24, 52, 104

  23. Change From Baseline in Joint Space Narrowing Score

    A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum scores for joint space narrowing (JSN) in the hands was 104 and in the feet 48 for a total possible score of 0 to 152. A lower change from Baseline indicated a better score. Analysis of covariance model included baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.

    Time frame: Baseline, Weeks 24, 52, 104

  24. Change From Baseline in Erosion Score

    A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. The maximum erosion score in the hands was 98 and in the feet 42 for a total possible score of 0 to 140. A lower number change from Baseline indicated a better score.

    Time frame: Baseline, Weeks 24, 52, 104

  25. Percentage of Participants Discontinuing Tocilizumab Due to Remission

    The percentage of participants who stopped treatment with tocilizumab due to remission.

    Time frame: Weeks 52, 104

  26. Percentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response

    Lack of Sufficient Therapeutic Response was defined as the patient not responding to the drug as expected.

    Time frame: Up to 3 years

  27. Percentage of Participants Who Withdrew Due to Safety Reasons

    Safety reasons were defined as adverse events, intercurrent illness or death. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.

    Time frame: Up to 3 years

  28. Change From Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)

    The RAQoL is a disease specific patient-reported outcome measure that determines the effect rheumatoid arthritis has on a patient's quality of life consisting of 30 questions that are answered either yes=1 or no=0 for a total possible score ranging from 0 (best) to 30 (worst). A negative change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 24, 52, 104

  29. Change From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS)

    The Academic Medical Center (AMC) Linear Disability Score (ALDS) evaluates the participant's ability to perform activities of daily life consisting of 77 questions answered yes or no . The question difficulty and the patient's ability are arranged on a single hierarchical linear scale. ALDS scores range from 10 to 90 with a higher score representing higher functional status. A positive change from Baseline indicated improvement.

    Time frame: Baseline, Weeks 104

  30. Area Under the Curve (AUC) From Baseline to Week 24 for ACR Response

    ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]. Area under the curve for ACR response to Week 24 was averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (≤ 5.5 and \> 5.5) as fixed factors.

    Time frame: Baseline to Week 24

  31. Area Under the Curve (AUC) From Baseline to Week 52 for ACR Response

    ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].Area under the curve for ACR response to Week 52 averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (\<=5.5 and \>5.5) as fixed factors.

    Time frame: Baseline to Week 52

  32. Time to Tocilizumab Remission

    The time in days from initial study drug treatment to tocilizumab remission that occurred when the patient discontinued treatment with tocilizumab.

    Time frame: 104 Weeks

  33. Time to Drug-Free Remission

    The time in days from initial study drug treatment to drug free remission that occurred when the participant was able to discontinue tocilizumab, methotrexate/placebo and open label disease-modifying antirheumatic drugs (DMARDS).

    Time frame: 104 Weeks

  34. Time to Flare After Tocilizumab Remission

    The time in days to a flare (recurrence of disease symptoms) after the patient discontinued treatment with tocilizumab.

    Time frame: 104 Weeks

  35. Time to Restart of Treatment After Discontinuation/Remission

    The time in days from treatment discontinuation or remission to the restart of treatment.

    Time frame: 104 Weeks

07

Results

Posted Jul 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneTocilizumab + MethotrexateTocilizumab + Placebo
Started279277
Received study drug277276
Completed week 24259250
Completed week 52243229
Completed week 104222201
Completed220195
Not completed5982
Withdrew: Adverse event2426
Withdrew: Death46
Withdrew: Withdrew consent912
Withdrew: Insufficient therapeutic response514
Withdrew: Refused treatment/did not cooperate77
Withdrew: Administrative/other56
Withdrew: Protocol violation26
Withdrew: Failure to return14
Withdrew: Did not receive study drug21

Outcome measures

PrimaryPercentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 2440.434.8
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.2055 (Cochran-Mantel-Haenszel test stratified by region and baseline DAS28 (≤5.5 and \>5.5).) · Odds ratio (or): 1.260 · 95% CI 0.882 to 1.799
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Regression, Logistic · p = 0.1894 (Logistic regression including treatment , region and baseline DAS28.) · Odds ratio (or): 1.270 · 95% CI 0.889 to 1.814Odds ratio is for Tocilizumab + Methotrexate relative to Tocilizumab + Placebo.
SecondaryPercentage of Participants With American College of Rheumatology (ACR20) Response

ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Number · Percentage of participants
Percentage of Participants With American College of Rheumatology (ACR20) Response
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Week 2471.570.3
Week 5270.869.2
Week 10465.759.4
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.8742Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.6212Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.0963Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
SecondaryPercentage of Participants With ACR50 Response

ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Number · Percentage of participants
Percentage of Participants With ACR50 Response
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Week 2445.540.2
Week 5250.255.4
Week 10452.746.4
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.2969Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.2215Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.1243Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
SecondaryPercentage of Participants With ACR70 Response

ACR70 response is defined as a ≥ 70% improvement (reduction) compared with Baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Number · Percentage of participants
Percentage of Participants With ACR70 Response
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Week 2424.525.4
Week 5231.431.2
Week 10434.329.3
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.6775Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.9976Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.2168Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
SecondaryPercentage of Participants With ACR90 Response

ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Number · Percentage of participants
Percentage of Participants With ACR90 Response
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Week 245.85.1
Week 5212.611.2
Week 10411.99.1
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.8369Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.6528Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.2546Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
SecondaryTime to First ACR20 Response

Time in days from first administration of study drug until ACR20 response. ACR20 response is defined as a ≥ 20% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
104 Weeks
Reported as:
Median · Days
Time to First ACR20 Response
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to First ACR20 Response57.0 (NA to NA)61.0 (57.0 to 84.0)
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.1018
SecondaryTime to First ACR50 Response

Time in days from first administration of study drug until ACR50 response. ACR50 response is defined as a ≥ 50% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate).

Time frame:
104 Weeks
Reported as:
Median · Days
Time to First ACR50 Response
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to First ACR50 Response140.0 (113.0 to 142.0)143.0 (137.0 to 169.0)
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.7176
SecondaryTime to First ACR70 Response

Time in days from first administration of study drug until ACR70 response. ACR70 response is defined as a ≥ 70% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
104 Weeks
Reported as:
Median · Days
Time to First ACR70 Response
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to First ACR70 Response284.0 (225.0 to 327.0)307.0 (253.0 to 338.0)
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.8526
SecondaryTime to First ACR90 Response

Time in days from first administration of study drug until ACR90 response. ACR90 response is defined as a ≥ 90% improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].

Time frame:
104 Weeks
Reported as:
Median · Days
Time to First ACR90 Response
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to First ACR90 ResponseNA (844.0 to NA)NA (986.0 to NA)
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.2217
SecondaryArea Under Curve (AUC) DAS28

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. AUC DAS28 was averaged over study days. Analysis of Covariance was adjusted for Baseline DAS28 as a covariate and treatment group and region as fixed factors. Higher calculated AUC values are worse (indicate higher disease activity).

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · Score on a scale*week
Area Under Curve (AUC) DAS28
Score on a scale*weekTocilizumab + MethotrexateTocilizumab + Placebo
Area Under Curve (AUC) DAS283.97 ± 0.0984.23 ± 0.092
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.0008 · Mean difference (final values): -0.26 · 95% CI -0.41 to -0.11Baseline DAS28 as a covariate.
SecondaryPercentage of Participants With Disease Activity Score 28 (DAS28) Remission

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission is defined as a DAS28 score \< 2.6.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Disease Activity Score 28 (DAS28) Remission
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Percentage of Participants With Disease Activity Score 28 (DAS28) Remission45.536.6
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Regression, Logistic · p = 0.0245 · Odds ratio (or): 1.490 · 95% CI 1.053 to 2.109Odds ratio is for Tocilizumab + Methotrexate relative to Tocilizumab + Placebo.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.0258 (Stratified by region and baseline DAS28 (≤ 5.5 and \> 5.5).) · Odds ratio (or): 1.482 · 95% CI 1.048 to 2.095
SecondaryPercentage of Participants With DAS28 Low Disease Activity (LDAS)

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. LDAS is defined as DAS28 ≤ 3.2.

Time frame:
Weeks 24, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With DAS28 Low Disease Activity (LDAS)
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Week 2461.751.4
Week 5262.557.2
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wald Chi-square · p = 0.0287Asymptotic test; parameter estimate is zero.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wald Chi-square · p = 0.2240Asymptotic test; parameter estimate is zero.
SecondaryChange From Baseline in DAS28 Score

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A higher value indicated higher disease activity. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · Score on a scale
Change From Baseline in DAS28 Score
Score on a scaleTocilizumab + MethotrexateTocilizumab + Placebo
Week 24-3.43 ± 1.326-3.21 ± 1.305
Week 52-3.74 ± 1.406-3.67 ± 1.291
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.0497
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.3918
SecondaryPercentage of Participants With Good or Moderate European League (EULAR) DAS28 Responses

The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) \[28 joints\], swollen joint count (SJC) \[28 joints\], patient's global assessment of disease activity \[visual analog scale: 0=no disease activity to 100=maximum disease activity\] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement. European League Against Rheumatism (EULAR) Good response: DAS28 ≤ 3.2 or a change from Baseline \< -1.2. EULAR Moderate response: DAS28 \> 3.2 to ≤ 5.1 or a change from Baseline \< -0.6 to ≥ -1.2.

Time frame:
Baseline, 24, 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Good or Moderate European League (EULAR) DAS28 Responses
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Week 2489.586.2
Week 5284.578.2
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.0019Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.1181Region and baseline DAS28 (≤5.5 and \>5.5) included as stratification variables.
SecondaryChange From Baseline in Swollen Joint Count

66 joints were assessed for swelling and joints are classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · Joint count
Change From Baseline in Swollen Joint Count
Joint countTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=255,246)-11.33 ± 8.042-11.74 ± 9.446
Week 52 (n=237,220)-12.29 ± 8.796-12.25 ± 8.949
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.7776 (P-value is from a 2-sided, Wilcoxon rank-sum test of no difference between the 2 treatment groups in change from baseline.)
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.8843
SecondaryChange From Baseline in Tender Joint Count

68 joints are assessed for tenderness and joints are classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · Joint count
Change From Baseline in Tender Joint Count
Joint countTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=255,246)-17.27 ± 13.358-17.00 ± 13.632
Week 52 (n=237,220)-19.45 ± 13.471-18.97 ± 12.768
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.9095
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.7179
SecondaryChange From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (VAS)

The patients global assessment of disease activity was assessed on a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Disease Activity Visual Analog Scale (VAS)
mmTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=255,246)-34.31 ± 25.677-32.42 ± 24.344
Week 52 (n=239,220)-38.92 ± 25.590-40.94 ± 26.211
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.3113
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.2931
SecondaryChange From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale (VAS)

The physician global assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · mm
Change From Baseline in Physician Global Assessment of Disease Activity Visual Analog Scale (VAS)
mmTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=249,244)-40.67 ± 19.500-38.46 ± 21.654
Week 52 (n=232,218)-44.18 ± 21.092-44.68 ± 21.400
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.2451 (P-value is from a 2-sided, Wilcoxon rank-sum test of no difference between the 2 treatment groups in change from baseline.)
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.8841
SecondaryChange From Baseline in Patient Global Assessment of Pain (VAS)

The patient assessed their pain using a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · mm
Change From Baseline in Patient Global Assessment of Pain (VAS)
mmTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=255,246)-29.34 ± 26.639-29.75 ± 24.918
Week 52 (239,220)-33.09 ± 26.933-38.38 ± 25.537
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.9655
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.0308
SecondaryChange From Baseline in Erythrocyte Sedimentation Rate (ESR)

Blood was collected for Erythrocyte Sedimentation Rate (ESR) (a test that assesses tissue inflammation) and was analyzed at a local laboratory. ESR was measured in millimeters/hour (mm/hr). A reduction in the level is considered an improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · mm/hr
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
mm/hrTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=255,246)-30.61 ± 24.187-29.10 ± 24.518
Week 52 (n=238,220)-31.81 ± 23.025-31.18 ± 24.527
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.5186
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.7706
SecondaryChange From Baseline in C-Reactive Protein (CRP)

Blood was collected for C-Reactive Protein (CRP) (a test for analysis of inflammatory and infectious disorders) and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL). A reduction in the level is considered an improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · mg/dL
Change From Baseline in C-Reactive Protein (CRP)
mg/dLTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=252,241)-1.37 ± 2.043-1.39 ± 2.206
Week 52 (n=236,221)-1.39 ± 1.943-1.40 ± 2.216
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.6067
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.6810
SecondaryChange From Baseline in the Health Assessment Questionnaire Disability Index

The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52
Reported as:
Mean · Score on a scale
Change From Baseline in the Health Assessment Questionnaire Disability Index
Score on a scaleTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=251,241)-0.56 ± 0.666-0.55 ± 0.531
Week 52 (n=235,213)-0.59 ± 0.713-0.67 ± 0.630
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.9323
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.1448
SecondaryChange From Baseline in Total Genant Modified Sharp Scores (GSS)

Radiographs were taken of each hand and foot at Baseline, Weeks 24, 52 and104 and were evaluated using the Genant modified method according to Sharp. Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Joint Narrowing Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum total erosion score in the hands is 98 and in the feet 42. The maximum scores for joint space narrowing (JSN) in the hands was104 and in the feet 48. The total score was the sum of scores for erosions and JSN. The maximum total modified GSS was 292. A lower number change from Baseline was better. Analysis of covariance model, with Baseline DAS28 as a covariate and treatment and site as fixed factors.

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Total Genant Modified Sharp Scores (GSS)
Score on a scaleTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n= 266,258)0.18 ± 0.1610.35 ± 0.152
Week 52 (n= 269,264)0.35 ± 0.3700.63 ± 0.350
Week 104 (n= 215,202)0.35 ± 0.3470.95 ± 0.320
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.2034 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.17 · 95% CI -0.43 to 0.09
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.3611 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.28 · 95% CI -0.88 to 0.32
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.0342 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.60 · 95% CI -1.16 to -0.05
SecondaryChange From Baseline in Joint Space Narrowing Score

A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). The maximum scores for joint space narrowing (JSN) in the hands was 104 and in the feet 48 for a total possible score of 0 to 152. A lower change from Baseline indicated a better score. Analysis of covariance model included baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Joint Space Narrowing Score
Score on a scaleTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n= 266, 258)0.16 ± 0.1210.19 ± 0.115
Week 52 (n= 269, 264)0.45 ± 0.3140.39 ± 0.297
Week 104 (n= 215, 202)0.38 ± 0.2180.70 ± 0.201
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.7095 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.04 · 95% CI -0.23 to 0.16
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.8147 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): 0.06 · 95% CI -0.45 to 0.57
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.0778 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.32 · 95% CI -0.67 to 0.04
SecondaryChange From Baseline in Erosion Score

A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. The maximum erosion score in the hands was 98 and in the feet 42 for a total possible score of 0 to 140. A lower number change from Baseline indicated a better score.

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Least squares mean · Score on a scale
Change From Baseline in Erosion Score
Score on a scaleTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=266,258)0.03 ± 0.0770.15 ± 0.072
Week 52 (n= 269,264)-0.09 ± 0.1250.25 ± 0.118
Week 104 (n= 215,202)-0.03 ± 0.1690.26 ± 0.156
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.0441 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.13 · 95% CI -0.25 to -0.00
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.0012 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.33 · 95% CI -0.54 to -0.13
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.0372 (Baseline x-ray and DAS28 as covariates and treatment group and region as fixed effects.) · Mean difference (final values): -0.29 · 95% CI -0.56 to -0.02
SecondaryPercentage of Participants Discontinuing Tocilizumab Due to Remission

The percentage of participants who stopped treatment with tocilizumab due to remission.

Time frame:
Weeks 52, 104
Reported as:
Number · Percentage of participants
Percentage of Participants Discontinuing Tocilizumab Due to Remission
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Week 52 (n=243,231)28.421.6
Week 104 (n=243,229)53.147.6
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.0694 · Difference: 6.75 · 95% CI -1.02 to 14.52Stratified by region and categorical baseline DAS28 (≤ 5.5 and \> 5.5).
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.1695
SecondaryPercentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response

Lack of Sufficient Therapeutic Response was defined as the patient not responding to the drug as expected.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Percentage of Participants Who Withdrew Due to Lack of Sufficient Therapeutic Response1.84.7
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.0496 · Difference: -2.91 · 95% CI -5.86 to 0.05Stratified by region and categorical baseline DAS28 (≤ 5.5 and \> 5.5).
SecondaryPercentage of Participants Who Withdrew Due to Safety Reasons

Safety reasons were defined as adverse events, intercurrent illness or death. An adverse event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study were reported as adverse events.

Time frame:
Up to 3 years
Reported as:
Number · Percentage of participants
Percentage of Participants Who Withdrew Due to Safety Reasons
Percentage of participantsTocilizumab + MethotrexateTocilizumab + Placebo
Percentage of Participants Who Withdrew Due to Safety Reasons9.711.2
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Cochran-Mantel-Haenszel · p = 0.5188 · Difference: -1.48 · 95% CI -6.59 to 3.62Stratified by region and categorical baseline DAS28 (≤ 5.5 and \> 5.5).
SecondaryChange From Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)

The RAQoL is a disease specific patient-reported outcome measure that determines the effect rheumatoid arthritis has on a patient's quality of life consisting of 30 questions that are answered either yes=1 or no=0 for a total possible score ranging from 0 (best) to 30 (worst). A negative change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 24, 52, 104
Reported as:
Mean · Score on a scale
Change From Baseline in Rheumatoid Arthritis Quality of Life Questionnaire (RAQoL)
Score on a scaleTocilizumab + MethotrexateTocilizumab + Placebo
Week 24 (n=146,135)-6.07 ± 8.005-5.19 ± 7.064
Week 52 (n=132,111)-7.28 ± 8.141-6.33 ± 7.691
Week 104 (n=87,74)-6.89 ± 8.691-5.24 ± 8.899
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.2652
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.1970
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Wilcoxon (Mann-Whitney) · p = 0.1671
SecondaryChange From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS)

The Academic Medical Center (AMC) Linear Disability Score (ALDS) evaluates the participant's ability to perform activities of daily life consisting of 77 questions answered yes or no . The question difficulty and the patient's ability are arranged on a single hierarchical linear scale. ALDS scores range from 10 to 90 with a higher score representing higher functional status. A positive change from Baseline indicated improvement.

Time frame:
Baseline, Weeks 104
Reported as:
Mean · Score on a scale
Change From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS)
Score on a scaleTocilizumab + MethotrexateTocilizumab + Placebo
Change From Baseline in Academic Medical Center (AMC) Linear Disability Scale (ALDS)2.42 ± 7.7730.91 ± 2.099
SecondaryArea Under the Curve (AUC) From Baseline to Week 24 for ACR Response

ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\]. Area under the curve for ACR response to Week 24 was averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (≤ 5.5 and \> 5.5) as fixed factors.

Time frame:
Baseline to Week 24
Reported as:
Least squares mean · Score on a scale*day
Area Under the Curve (AUC) From Baseline to Week 24 for ACR Response
Score on a scale*dayTocilizumab + MethotrexateTocilizumab + Placebo
Area Under the Curve (AUC) From Baseline to Week 24 for ACR Response18.95 ± 4.22013.74 ± 3.979
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.1110 · Adjusted mean difference (wald ci): 5.22 · 95% CI -1.20 to 11.64The analysis of covariance model included treatment group, region and baseline DAS28 (≤ 5.5 and \> 5.5) as fixed factors.
SecondaryArea Under the Curve (AUC) From Baseline to Week 52 for ACR Response

ACR response was defined as an improvement (reduction) compared with baseline for both total joint count-68 joints and swollen joint count-66 joints, and for three of five variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) where 0=no pain to 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where: 0=no disease activity to 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant \[either C-reactive protein or Erythrocyte Sedimentation Rate\].Area under the curve for ACR response to Week 52 averaged over study days. Analysis of covariance model includes treatment group, region and baseline DAS28 (\<=5.5 and \>5.5) as fixed factors.

Time frame:
Baseline to Week 52
Reported as:
Least squares mean · Score on a scale*day
Area Under the Curve (AUC) From Baseline to Week 52 for ACR Response
Score on a scale*dayTocilizumab + MethotrexateTocilizumab + Placebo
Area Under the Curve (AUC) From Baseline to Week 52 for ACR Response30.48 ± 4.90132.59 ± 4.611
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · ANCOVA · p = 0.6027 · Adjusted mean difference (wald ci): -2.11 · 95% CI -10.07 to 5.85The analysis of covariance model included treatment group, region and baseline DAS28 (≤ 5.5 and \> 5.5) as fixed factors.
SecondaryTime to Tocilizumab Remission

The time in days from initial study drug treatment to tocilizumab remission that occurred when the patient discontinued treatment with tocilizumab.

Time frame:
104 Weeks
Reported as:
Median · Days
Time to Tocilizumab Remission
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to Tocilizumab Remission645.0 (360 to 855)786.0 (351 to 829)
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.1695
SecondaryTime to Drug-Free Remission

The time in days from initial study drug treatment to drug free remission that occurred when the participant was able to discontinue tocilizumab, methotrexate/placebo and open label disease-modifying antirheumatic drugs (DMARDS).

Time frame:
104 Weeks
Reported as:
Median · Days
Time to Drug-Free Remission
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to Drug-Free RemissionNA (366 to 1121)NA (365 to 1151)
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.0096
SecondaryTime to Flare After Tocilizumab Remission

The time in days to a flare (recurrence of disease symptoms) after the patient discontinued treatment with tocilizumab.

Time frame:
104 Weeks
Reported as:
Median · Days
Time to Flare After Tocilizumab Remission
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to Flare After Tocilizumab Remission113.0 (25 to 400)84.0 (1 to 415)
Statistical analysis
  • Tocilizumab + Methotrexate vs Tocilizumab + Placebo · Log Rank · p = 0.0734
SecondaryTime to Restart of Treatment After Discontinuation/Remission

The time in days from treatment discontinuation or remission to the restart of treatment.

Time frame:
104 Weeks
Reported as:
Median · Days
Time to Restart of Treatment After Discontinuation/Remission
DaysTocilizumab + MethotrexateTocilizumab + Placebo
Time to Restart of Treatment After Discontinuation/Remission113.0 (87.0 to 150.0)81.0 (58.0 to 91.0)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tocilizumab + Methotrexate—49/277 (17.7%)189/277 (68.2%)
Tocilizumab + Placebo—48/276 (17.4%)179/276 (64.9%)
Most frequent serious events
Showing 10 of 112
Most frequent serious events
EventTocilizumab + MethotrexateTocilizumab + Placebo
PneumoniaInfections and infestations0/2773/276
BronchopneumoniaInfections and infestations3/2770/276
ErysipelasInfections and infestations0/2772/276
Transient ischaemic attackNervous system disorders1/2772/276
Femoral neck fractureInjury, poisoning and procedural complications1/2772/276
Tendon ruptureInjury, poisoning and procedural complications0/2772/276
Acute myocardial infarctionCardiac disorders0/2772/276
Transaminases increasedInvestigations2/2772/276
Septic shockInfections and infestations2/2770/276
Cardiac failure congestiveCardiac disorders2/2771/276
Most frequent other events
Showing 10 of 20
Most frequent other events
EventTocilizumab + MethotrexateTocilizumab + Placebo
NasopharyngitisInfections and infestations43/27740/276
HypercholesterolemiaMetabolism and nutrition disorders34/27733/276
Alanine aminotransferase increasedInvestigations33/27715/276
Upper respiratory tract infectionInfections and infestations31/27725/276
Transaminases increaseInvestigations30/27715/276
Back painMusculoskeletal and connective tissue disorders29/27721/276
NauseaGastrointestinal disorders27/2779/276
Urinary tract infectionInfections and infestations23/27718/276
DiarrhoeaGastrointestinal disorders20/27721/276
HeadacheNervous system disorders18/27721/276

Baseline characteristics

Baseline measures are based on the Safety Population and include all randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)Tocilizumab + MethotrexateTocilizumab + PlaceboTotal
Mean53.0 ± 13.4053.6 ± 11.9153.3 ± 12.67
Sex: Female, Male
Sex: Female, Male(Participants)Tocilizumab + MethotrexateTocilizumab + PlaceboTotal
Female227217444
Male5059109
08

Study locations

137 sites
  • Santa Monica, California 90404, United States
  • Upland, California 91786, United States
  • Whittier, California 90606, United States
  • Aventura, Florida 33180, United States
  • Naples, Florida 34102, United States
  • Orange Park, Florida 32073, United States
  • Plantation, Florida 33317, United States
  • Sarasota, Florida 34239, United States
  • South Miami, Florida 33143, United States
  • Tamarac, Florida 33321, United States
  • Eagan, Minnesota 55121, United States
  • Las Vegas, Nevada 89128, United States
  • Mayfield, Ohio 44143, United States
  • Middleburg Heights, Ohio 44130, United States
  • Oklahoma City, Oklahoma 73104, United States
  • West Reading, Pennsylvania 19611, United States
  • Greenville, South Carolina 29601, United States
  • Nashville, Tennessee 37205, United States
  • Houston, Texas 77004, United States
  • San Antonio, Texas 78217, United States
  • Spokane, Washington 99204, United States
  • Belo Horizonte, MG 30130-100, Brazil
  • Porto Alegre, RS 90035-903, Brazil
  • Sao Paulo, SP 04026-000, Brazil
  • Sao Paulo, SP 04039-004, Brazil
  • Sao Paulo, SP 05403-000, Brazil
  • Rijeka, 51000, Croatia
  • Zagreb, 10000, Croatia
  • Frederiksberg, 2000, Denmark
  • Hellerup, 2900, Denmark
  • Køge, 4600, Denmark
  • Tallinn, 11312, Estonia
  • Tallinn, 13419, Estonia
  • Abbeville, 80142, France
  • Boulogne-billancourt, 92104, France
  • Brest, 29609, France
  • Echirolles, 38434, France
  • Le Kremlin Bicetre, 94275, France
  • Le Mans, 72037, France
  • Marseille, 13285, France
  • Marseille, 13385, France
  • Monaco, 98012, France
  • Nantes, 44035, France
  • Nice, 06202, France
  • Paris, 75571, France
  • Paris, 75679, France
  • Pierre Benite, 69495, France
  • Vandoeuvre-les-nancy, 54511, France
  • Aachen, 52064, Germany
  • Berlin, 10117, Germany
  • Berlin, 13125, Germany
  • Dresden, 01307, Germany
  • Erlangen, 91054, Germany
  • Hamburg, 22081, Germany
  • Jena, 07747, Germany
  • Köln, 50924, Germany
  • Muenchen, 80336, Germany
  • Ratingen, 40882, Germany
  • Wuerzburg, 97080, Germany
  • Athens, 11527, Greece
  • Thessaloniki, 54636, Greece
  • Thessaloniki, 54642, Greece
  • Afula, 18101, Israel
  • Beer Sheva, 8410101, Israel
  • Haifa, 31048, Israel
  • Haifa, 34354, Israel
  • Haifa, 34362, Israel
  • Kfar Saba, 44281, Israel
  • Ramat-Gan, 52621, Israel
  • Rishon Lezion, Israel
  • Tel Aviv, 6423906, Israel
  • Ancona, 60020, Italy
  • Bari, 70124, Italy
  • Perugia, 06122, Italy
  • Prato, 59100, Italy
  • Roma, 00168, Italy
  • Bauska, 3901, Latvia
  • Daugavpils, 5417, Latvia
  • Liepaja, 3400, Latvia
  • Riga, 1006, Latvia
  • Riga, 1038, Latvia
  • Riga, LV-1002, Latvia
  • Amsterdam, 1081 HV, Netherlands
  • Amsterdam, 1105 AZ, Netherlands
  • Leiden, 2333 ZA, Netherlands
  • Maastricht, 6202 AZ, Netherlands
  • Nijmegen, 6525 GA, Netherlands
  • Utrecht, 3584 CX, Netherlands
  • Drammen, 3004, Norway
  • Gjettum, 1346, Norway
  • Kristiansand, 4604, Norway
  • Lillehammer, 2609, Norway
  • Moss, 1535, Norway
  • Oslo, 0319, Norway
  • Bucharest, 011172, Romania
  • Bucuresti, 020983, Romania
  • Barnaul, 656024, Russian Federation
  • Ekaterinburg, 620102, Russian Federation
  • Irkutsk, 664047, Russian Federation
  • Izhevsk, 426009, Russian Federation

Showing the first 100 of 137 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Mola EM, Schett G, Amital H, Navarro-Sarabia F, Hou A, Bernasconi C, Huizinga TW. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013 Jan;72(1):43-50. doi: 10.1136/annrheumdis-2011-201282. Epub 2012 May 5. PubMed 22562983 ↗
  • Dougados M, Kissel K, Conaghan PG, Mola EM, Schett G, Gerli R, Hansen MS, Amital H, Xavier RM, Troum O, Bernasconi C, Huizinga TW. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis. 2014 May;73(5):803-9. doi: 10.1136/annrheumdis-2013-204761. Epub 2014 Jan 28. PubMed 24473673 ↗
  • Dougados M, Huizinga TW, Choy EH, Bingham CO 3rd, Aassi M, Bernasconi C. Evaluation of the Disease Activity Score in Twenty-Eight Joints-Based Flare Definitions in Rheumatoid Arthritis: Data From a Three-Year Clinical Trial. Arthritis Care Res (Hoboken). 2015 Dec;67(12):1762-6. doi: 10.1002/acr.22633. PubMed 26037777 ↗
  • Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, Troum O, Aassi M, Bernasconi C, Dougados M. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015 Jan;74(1):35-43. doi: 10.1136/annrheumdis-2014-205752. Epub 2014 Aug 28. PubMed 25169728 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Aug 2010 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2014, 3 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2008
First posted
Dec 17, 2008
Start
Mar 2009
Primary completionActual
Aug 2010
CompletionActual
Jan 2013
Results first posted
Jul 18, 2014
Last update
Jul 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00810199
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 17, 2008
Start date
Mar 2009
Primary completion
Aug 2010
Completion
Jan 2013
Results posted
Jul 18, 2014
Last update
Jul 18, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methotrexate

Start the discussion